Authors

Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

Beyond the surface: Tackling complex dry eye cases

Ophthalmologists weigh in on evolving diagnostic tools, emerging therapies, and practical approaches for managing today’s most challenging ocular-surface cases.

Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Q&A: Evolving approaches to geographic atrophy management

Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration.

SAHARA trial demonstrates sustained TearCare benefits for evaporative DED

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

Global trial equity: How LMIC data is reshaping US ophthalmology research

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing patient communication, documentation, and education, while also addressing ethical considerations and potential future applications in glaucoma care.

Envision Summit 2025: Eradicating TRD

At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.

AAO 2025: The rise of presbyopia research

Hipsley shares insights into ocular biomechanics and dynamic range of focus, that can help the field to work toward vision restoration and increase eye health.

EyePoint receives second consecutive positive recommendation from DSMC

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for improved patient outcomes.

EnVision Summit 2025: Complications in glaucoma surgery

At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery.